N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug
Autor: | Piotr Wlaź, Kinga Gawel, Camila V. Esguerra, Katarzyna Socała, Michał Abram, Dorota Nieoczym, Mirosław Zagaja, Bartłomiej Szulczyk, Gniewomir Latacz, Krzysztof Kamiński, Jarogniew J. Łuszczki, Aleksandra Szewczyk, Annamaria Lubelska, Mateusz Pieróg, Marta Andres-Mach, Marcin Jakubiec, Anna Rapacz |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Male isobolographic studies Levetiracetam Pyrrolidines ADME-Tox properties medicine.medical_treatment Drug-resistant epilepsy Pharmacology PTZ-kindling model of epilepsy 03 medical and health sciences Epilepsy chemistry.chemical_compound Mice 0302 clinical medicine drug-resistant epilepsy Lacosamide Seizures medicine Animals Pharmacology (medical) Valproic Acid CYP3A4 Behavior Animal Dose-Response Relationship Drug Kindling medicine.disease electrophysiology zebrafish Propanamide In vitro 3. Good health 030104 developmental biology Anticonvulsant chemistry Ethosuximide Pentylenetetrazole Original Article Anticonvulsants Neurology (clinical) Kindling model 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Neurotherapeutics |
ISSN: | 1878-7479 1933-7213 |
Popis: | In our recent studies, we identified compound N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) as a broad-spectrum hybrid anticonvulsant which showed potent protection across the most important animal acute seizure models such as the maximal electroshock (MES) test, the subcutaneous pentylenetetrazole (s.c. PTZ) test, and the 6-Hz (32 mA) test in mice. Therefore, AS-1 may be recognized as a candidate for new anticonvulsant effective in different types of human epilepsy with a favorable safety margin profile determined in the rotarod test in mice. In the aim of further pharmacological evaluation of AS-1, in the current study, we examined its activity in the 6-Hz (44 mA) test, which is known as the model of drug-resistant epilepsy. Furthermore, we determined also the antiseizure activity in the kindling model of epilepsy induced by repeated injection of pentylenetetrazole (PTZ) in mice. As a result, AS-1 revealed relatively potent protection in the 6-Hz (44 mA) test, as well as delayed the progression of kindling induced by repeated injection of PTZ in mice at doses of 15 mg/kg, 30 mg/kg, and 60 mg/kg. Importantly, the isobolographic analysis showed that a combination of AS-1 and valproic acid (VPA) at the fixed ratio of 1:1 displayed a supra-additive (synergistic) interaction against PTZ-induced seizures in mice. Thus, AS-1 may be potentially used in an add-on therapy with VPA. Moreover, incubation of zebrafish larvae with AS-1 substantially decreased the number, cumulative but not the mean duration of epileptiform-like events in electroencephalographic assay. Finally, the in vitro ADME-Tox studies revealed that AS-1 is characterized by a very good permeability in the parallel artificial membrane permeability assay test, excellent metabolic stability on human liver microsomes (HLMs), no significant influence on CYP3A4/CYP2D6 activity, and moderate inhibition of CYP2C9 in a concentration of 10 μM, as well as no hepatotoxic properties in HepG2 cells (concentration of 10 μM). Electronic supplementary material The online version of this article (10.1007/s13311-019-00773-w) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |